Genomic and transcriptomic quality control for an autologous iPSC-derived cell therapy for Parkinson’s disease
Bratt-Leal et al. report the preclinical data supporting initiation of a clinical trial investigating autologous dopaminergic neuron precursor cell therapy for moderate to advanced Parkinson’s disease patients.